Clinical trials: Synucleinopathy
Parkinson's Disease (PD)
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations
This is a prospective, single-arm, single-dose clinical study designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-N001 Injection in patients with…
- Trial name
- NCT07685444
- Testing
- LY-N001 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Lingyi Biotech Co., Ltd.
Early Stage Parkinson's Disease
SLV308 for Treatment of Patients With Early Parkinson's Disease
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD.
- Trial name
- NCT00269516
- Testing
- pardoprunox
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson Disease
LFP Beta aDBS Feasibility Study
The purpose of this study is to use local field potentials as control signals for adjusting DBS stimulation settings under varying patient states and to assess patient outcomes.
- Trial name
- NCT03446833
- Testing
- The LFP Beta aDBS System
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MedtronicNeuro
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
This study will evaluate the effects of immediate release (IR) carbidopa levodopa versus the effects of immediate-release carbidopa/levodopa on ERP parameters in patients with idiopathic PD.
- Trial name
- NCT00601978
- Testing
- carbidopa/levodopa, Carbidopa/Levodopa/Entacapone
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy
- Trial name
- ATTUNED (NCT03331848)
- Testing
- PXT002331 - 20mg
- Sponsor
- Prexton Therapeutics
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers
The primary study objective is to establish the safety and tolerability of MT101-5 after a single and multiple dose administrations in healthy volunteers.
- Trial name
- NCT05844787
- Testing
- MT101-5
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mthera Pharma Co., Ltd.
Parkinson Disease, Dyskinesias
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This phase IIb study is designed to determine the safe and efficacious dose or dose range of AFQ056 for the treatment of patients with moderate to severe Parkinson's disease with L-Dopa induced dyskinesias.
- Trial name
- NCT00986414
- Testing
- AFQ056
- Where
- 47 sites in Australia, Canada and 6 more
- Volunteers
- 260 people
- Sponsor
- Novartis
Parkinson Disease, Parkinson's Disease
Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment…
- Trial name
- NCT07371338
- Testing
- IPS101A
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Innopeutics Corporation
Parkinson's Disease
Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. Up to 5 cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
- Trial name
- NCT04043338
- Testing
- XC130-A10H
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Xoc Pharmaceuticals
Parkinson's Disease
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease
- Trial name
- NCT00163085
- Testing
- NR2B NMDA Antagonist CP-101,606 (traxoprodil)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.
- Trial name
- APEX-PD (NCT00880620)
- Testing
- IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 381 people
- Sponsor
- Impax Laboratories, LLC
Parkinson Disease
A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's
This study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries.
- Trial name
- NCT00331149
- Testing
- Ropinirole prolonged release, ropinirole immediate release
- Where
- 81 sites in Bulgaria, Canada and 12 more
- Volunteers
- 343 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Parkinson Disease
Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease
The purpose of this study is to describe the safety and efficacy of opicapone plus standard of care in elderly patients with PD in the real-world setting
- Trial name
- NCT03959540
- Testing
- Opicapone, Levodopa (L-DOPA) + Standard care
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii.
- Trial name
- NCT00489255
- Testing
- Tigan®
- Where
- 27 sites in United States
- Volunteers
- 117 people
- Sponsor
- Ipsen
Parkinson Disease, Dyskinesia, Drug-Induced
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind…
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
- Trial name
- NCT05116813
- Testing
- Dipraglurant
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Addex Pharma S.A.
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease
The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age…
- Trial name
- NCT02263885
- Testing
- ExAblate Transcranial System
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Parkinson Disease
Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients
This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced…
- Trial name
- AMBLED (NCT03162874)
- Testing
- PXT002331 - dose 1, PXT002331 - dose 2
- Where
- 45 sites in Austria, France and 4 more
- Volunteers
- 157 people
- Sponsor
- Prexton Therapeutics
Parkinson's Disease
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations.
- Trial name
- NCT00368108
- Testing
- 2 mg perampanel, 4 mg perampanel
- Where
- 114 sites in United States, Canada
- Volunteers
- 752 people
- Sponsor
- Eisai Inc.